<DOC>
	<DOCNO>NCT01993784</DOCNO>
	<brief_summary>Nimotuzumab IgG1 humanize monoclonal antibody recognize epitope locate extra cellular domain human epidermal growth factor receptor ( EGFR ) . Clinical efficacy show adult head neck cancer . The study assess safety efficacy different dosage Nimotuzumab second late- line treatment patient locally advance metastatic esophageal squamous cell carcinoma .</brief_summary>
	<brief_title>Study Nimotuzumab Treat Esophageal Squamous Cell Carcinoma .</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Neoplasms , Squamous Cell</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<criteria>Histologically confirm esophageal squamous carcinoma , fail first second line chemothrepay Age 18 75 year old Measurable disease accord RECIST criterion ( diameter lesion 10mm spiral CT MRI , 20mm common CT , date image le 15 day enrollment ) Life expectancy ≥3 month Karnofsky performance status ≥80 WBC &gt; 3,000/mm3 , absolute neutrophil count ≥1500/mm3 , platelet &gt; 100,000/mm3 , Hb &gt; 9g/dl，Bilirubin level &lt; 1.0 time ULN，Serum creatinine &lt; 1.0 time ULN，ALT AST &lt; 2.5 time ULN ，AKP &lt; 2.5 time ULN ， ( ≤5 time ULN patient liver metastasis ) ( within 7 day enrollment ) No sever complication , active gastrointestinal bleeding , perforation , jaundice , obstruction , noncancerous fever＞38℃； Normal ECG/cardiac function Good compliance Having sign inform consent No previous systemic therapy metastatic esophageal squamous carcinoma Known hypersensitivity study drug Tumor length≥10cm , liver metastasis cover 50 % liver , lung metastasis cover 25 % lung No measurable lesion , eg . pleural fluid ascites Only Other previous malignancy within 5 year , except nonmelanoma skin cancer Heart failure sever organ dysfunction , eg . coronary artery disease , myocardial infarction within last 6 month Brain bone metastasis Chronic diarrhea Mentally abnormal disable cognition , include CNS metastasis Pregnancy lactation period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>